Prostate cancer
Pharmacokinetics, Pharmacodynamics, and Safety study of TOL3022 in Patients with Advanced Prostate Cancer
Who can joinAsk the trial team
AgeAsk the trial team
Kind of studyStudy of how care is given
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Contact hospital
The registry names this hospital as the trial's main contact. Ask them which hospitals are taking patients.
CBCC Global ResearchIndiaDirections ↗
Registry summary (technical)
An Open-label, Single-dose Bioavailability Study to Evaluate Pharmacokinetics, Pharmacodynamics, and Safety Following Subcutaneous Injection of TOL3022 in Patients with Advanced Prostate Cancer - NIL
Sponsor: Tolmar, Inc,
CTRI/2025/11/098006 on CTRI, India's trial registry
Source: Clinical Trials Registry – India (CTRI), via WHO ICTRP, data of 12 Oct 2026
Last updated on the registry 1 Jun 2026 · read by us 5 Nov 2026